Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. 19423538 2009
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE No significant difference was observed between MIC and CIN III group concerning HPV infection and p53 polymorphism. 15361203 2004
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 AlteredExpression disease BEFREE The sample had a high rate of high-risk HPV detected in benign and malignant lesions; high cervical cancer burden; HPV 16 DNA integration in all except one case of cancer; p53 gene changes in CIN III and in invasive cancer cases associated with DNA integration. 12870053 2003
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Changes in the p53 gene were observed in a case of squamous carcinoma and a case of asymptomatic cervical intraepithelial neoplasia grade III (CIN III). 11836549 2002
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Neither specific HPV-16 350G/T variants nor specific p53 genotypes were associated with a higher risk of developing CIN III or cervical cancer. 10644829 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE Either HPV infection or accumulation of p53 was found in 16.7% (5/30) of the cases of normal or metaplastic cervix, 29.4% (5/17) of CIN I, 45.0% (9/20) of CIN II, 86.5% (32/37) of CIN III and 87.0% (20/23) of ISCC cases. 7697216 1995
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 CausalMutation disease CGI
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.320 GeneticVariation disease BEFREE Twenty percent of CIN III and 41% of InCa had patterns compatible with Ha-ras mutations. 12878090 2003
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.320 Biomarker disease BEFREE These results established the normal distribution and expression patterns of p53, p62myc, and p21ras within 395 cervical biopsy samples representing normal through CIN III histology. 9762942 1998
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.320 CausalMutation disease CGI
Entrez Id: 5457
Gene Symbol: POU4F1
POU4F1
0.310 Biomarker disease CTD_human The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix. 20190800 2010
Entrez Id: 5457
Gene Symbol: POU4F1
POU4F1
0.310 AlteredExpression disease BEFREE The elevated levels of Brn-3a in the CIN3 patient samples, together with the activating effect of Brn-3a on HPV-16 and -18 oncogene expression, suggest that induction of this factor is involved in activating HPV-16 and -18 oncogene expression in the cervix, and hence in the production of cervical cancers induced by HPV. 9541499 1998
Entrez Id: 4524
Gene Symbol: MTHFR
MTHFR
0.300 Biomarker disease CTD_human Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. 17303386 2007
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.300 CausalMutation disease CGI
Entrez Id: 2261
Gene Symbol: FGFR3
FGFR3
0.300 CausalMutation disease CGI
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 Biomarker disease BEFREE The prevalence of Group 1/2A HPV types increased with increasing CIN grade and accounted for 96.05% of the CIN 3+ lesions, while HPV16 accounted for 71.1%. 28431558 2017
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 GeneticVariation disease BEFREE Nearly half (48.3%) of CIN 2+ and 80.4% of CIN 3+ lesions missed or under-diagnosed by colposcopy had viral load in intermediate to high ranges. 26566949 2016
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 Biomarker disease BEFREE Specimens that were positive for p16<sup>INK4A</sup> expression were 5.3 and 16.6 times more likely to be diagnosed as CIN 2 and CIN 3 lesions, respectively, compared to CIN 1 lesions. 27479745 2016
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 GeneticVariation disease BEFREE The rare occurrence of histology-proven cervical intraepithelial neoplasia grade 3 (CIN 3) or invasive cancer with a negative HC2 result is known. 23959298 2014
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 GeneticVariation disease BEFREE In the follow-up, we detected 3 p16-positive high-grade squamous epithelial lesions (CIN-II and CIN-III) in the CIN-I/p16-negative group and 5 p16-positive high-grade squamous epithelial lesions cases in the CIN-II/p16-negative group. 24656093 2014
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 GeneticVariation disease BEFREE The aim of this study was to assess the prognostic value of p16(INK4a) as a marker of post-conization relapse in patients treated for cervical intraepithelial neoplasia grade 3 (CIN 3). 23763281 2014
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 Biomarker disease BEFREE CIN 1 staining patterns were typified (67.7% specimens) by abundant diffusely staining nuclei in the upper epithelial layers; CIN 2 lesions mostly (66.7%) showed a combination of superficial diffuse-stained nuclei and multiple dot-like nuclear and cytoplasmic signals throughout the epithelium; CIN 3 lesions were characterized (87.5%) by multiple dot-like nuclear and cytoplasmic signals throughout the epithelial thickness and absence/scarcity of diffusely staining nuclei (trend across CIN grades: P<0.0001). 24625757 2014
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 Biomarker disease BEFREE The prevalence of Group 1/2A HPV types increased with increasing CIN grade and attributed 78.3% (95% CI 53.4-89.9) of the CIN 3+ lesions, while HPV 16 attributed 55.8% (40.0-67.5) of them. 24136148 2013
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 Biomarker disease BEFREE In women younger than 30 years, the sensitivity of E6, E7 mRNA for CIN 2+ lesions was 88% for CIN 2+ and 92% for CIN 3+ lesions. 22849745 2012
Entrez Id: 57026
Gene Symbol: PDXP
PDXP
0.100 Biomarker disease BEFREE HC2 and GP5+/6+, have shown in large clinical trials that they perform better in the detection of CIN 2+/CIN 3+ lesions than cytology and thus have been clinically validated. 20129067 2009